Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.04 | -8.27922077922 | 24.64 | 25.55 | 22.2639 | 326360 | 24.4741905 | CS |
4 | 1.61 | 7.67031919962 | 20.99 | 25.55 | 19.88 | 298808 | 22.85434221 | CS |
12 | 5.88 | 35.1674641148 | 16.72 | 25.55 | 16.16 | 291523 | 22.43085702 | CS |
26 | 9.69 | 75.0580945004 | 12.91 | 26 | 10.9001 | 267588 | 20.50367394 | CS |
52 | 4.16 | 22.5596529284 | 18.44 | 26 | 9.8 | 192052 | 18.38568562 | CS |
156 | -1.6 | -6.61157024793 | 24.2 | 26 | 9.8 | 192229 | 19.04871496 | CS |
260 | -1.6 | -6.61157024793 | 24.2 | 26 | 9.8 | 192229 | 19.04871496 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.